| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2025―Aug―25 |
SARS-CoV-2 Mediated Dysregulation of Drug Processing Genes is Dependent on Pathogenic Variants, Target Site of Infection, Age, and Sex |
Chukwunonso K. Nwabufo |
| 2 |
[GO] |
2024―Oct―29 |
Uncovering the Impact of COVID-19 Mediated Bidirectional Dysregulation of CYP3A4 on Systemic and Pulmonary Drug Concentrations Using Physiologically Based Pharmacokinetic Modeling |
Chukwunonso K. Nwabufo |
| 3 |
[GO] |
2023―Sep―14 |
The Metabolism of Lufotrelvir, a Prodrug Investigated for the Treatment of SARS-COV2 in Humans Following Intravenous Administration |
Narayan Cheruvu, Esther van Duijn, Pieter A. Spigt, Ioana M. Barbu, Sima S. Toussi, Klaas Schildknegt, et al. (+2) Rhys M. Jones, R. Scott Obach |
| 4 |
[GO] |
2022―Oct―31 |
COVID-19 Vaccines and the Virus: Impact on Drug Metabolism and Pharmacokinetics |
Eliza R McColl, Maria A. Croyle, William C. Zamboni, William G Honer, Mark Heise, Micheline Piquette-Miller, Kerry B. Goralski |
| 5 |
[GO] |
2022―Aug―30 |
The COVID-19 Oral Drug Molnupiravir Is a CES2 Substrate: Potential Drug-Drug Interactions and Impact of CES2 Genetic Polymorphism In Vitro |
Yue Shen, William Eades, William Liu, Bingfang Yan |
| 6 |
[GO] |
2022―Feb―13 |
Disposition of PF-07321332 (Nirmatrelvir), an Orally Bioavailable Inhibitor of SARS-CoV-2 3CL Protease, across Animals and Humans |
Heather Eng, Alyssa L Dantonio, Eugene P Kadar, R. Scott Obach, Li Di, Jian Lin, et al. (+7) Nandini C. Patel, Britton Boras, Gregory S. Walker, Jonathan J. Novak, Emi Kimoto, Ravi Shankar P Singh, Amit S. Kalgutkar |
|
